Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND007 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. A prospective, single-arm, dose-escalation exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of different doses of REGEND007 cell therapy administered by intravenous infusion in the treatment of COPD, and to recommend appropriate treatment doses for subsequent clinical studies.

NCT Number	NCT07355868
Lead Sponsor	Regend Therapeutics
Conditions	Chronic Obstructive Pulmonary Disease (COPD)
Enrollment	12 participants
Start Date	2026-03-19
Primary Completion	2026-10-15 (estimated)
Study Completion	2026-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-23